Erleada

Active Substance

apalutamide

Holder

Janssen-Cilag NV

Status

Running

Indication

in combination with androgen deprivation therapy (ADT) for the treatment of adult patients with metastatic hormone-sensitive prostate cancer (mHSPC)

Public documents

Approbation

Information for the patient

Informed consent

Last update

13/11/2020
Last updated on 13/04/2021